In a phase I clinical trial focusing on Glypican-3 (GPC3), a significant HCC-associated antigen, as a promising target for heavily treated HCC patients CT017 CAR T cells co-expressing CAR-GPC3 and RUNX3 were engineered to induce CD8+ T-cell infiltration within the cancer microenvironment. The gene discussed is RUNX3; the disease is hepatocellular carcinoma.